featured
Fosnetupitant vs Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
J. Clin. Oncol 2021 Nov 18;n/a(n/a)JCO2101315, A Hata, I Okamoto, N Inui, M Okada, M Morise, K Akiyoshi, M Takeda, Y Watanabe, S Sugawara, N Shinagawa, K Kubota, T Saeki, T TamuraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.